Table 2 Evidence profile for sharp reuse prevention syringes versus single use disposable syringes when used by healthcare workers to deliver intramuscular, subcutaneous or intradermal injections
Quality assessment | â„– of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
â„– of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | IM/SC/I Reuse prevention safety devices | no safety devices | Relative (95Â % CI) | Absolute (95Â % CI) | ||
HIV, HBV and HCV infections amongst patients: not reported | ||||||||||||
| Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Critical |
Reuse of syringes: not reported | ||||||||||||
| Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Important |
NSI per HCW | ||||||||||||
1 | Observational | Not serious | Not serious | Not serious | Not serious | Large effect size | 35/3253 (1.1)% | 77/2829 (2.7)% | RR 0.4 (0.27 to 0.59) | 16 fewer per 1000 (from 11 fewer to 20 fewer) | Moderate | Important |